Teva Pharmaceuticals, in collaboration with Vivian Corporation, are pleased to announce the launch of Salamol Easi-breathe®, a breath-actuated inhaler device, for the relief of acute asthma symptoms including wheezing, breathlessness and tightness of the chest, or before allergen exposure or exercise, in children, adolescents and adults.

Nearly 80% of asthma patients make at least one error when using a pMDI1. Poor inhaler technique is a common problem in asthma, this is why Teva believe it’s their duty to make inhalers so simple and intuitive patients can’t help but use them well. That’s why Easi-Breathe® has only three instructions:

Open, Breathe, Close.

The new, innovative and easy to use inhaler device, Salamol Easi-breathe® contains 100mcg Salbutamol/inhalation.

View the video to learn more

{module [593]} 

Click here for full SmPC

About Teva Pharmaceuticals

As a forward looking global pharmaceutical company, Teva are committed to R&D with new respiratory products under development in the following areas: • Intuitively-designed inhaler devices • ICS and LABA fixed-dose combination • LAMA (long-acting muscarinic antagonist) • Interleukin antagonist

For more information contact

Senior Medical Representative: Marion Zammit marionzammit@viviancorp.com

Regulatory Affairs: Dr Romina Briffa rominabriffa@viviancorp.com

Marketing: Hannah Cremona hannahcremona@viviancorp.com

Healthcare professionals are asked to report any suspected adverse reactions via: ADR Reporting, The Medicines Authority, Post-Licensing Directorate, 203 Level 3, Rue D’Argens, Gżira GŻR1368.

Website: www.medicinesauthority.gov.mt,

e-mail: postlicensing.medicinesauthority@gov.mt

1Hammerlein, A et al; (2011); ‘Pharmacist-led intervention study to improve inhalation technique in Asthma and COPD patients’; Journal of Evaluation in Clinical Practice, Vol 17(1); p 61-70; Blackwell Publishing Limited.

TEVA Pharmaceuticals Ireland,

Floor 1, Wing A, Building 1, Finnabair Business & Technology Park, Dundalk, Co. Louth, Ireland.

Distributed by Vivian Corporation T:21320338 W: www.viviancorp.com E: info@viviancorp.com.

MA/EB/15/0001 Date of Preparation: January 2015